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Introduction
Uterine leiomyosarcoma (LMS) is a rare cancer originated 
from smooth muscle lining the walls of the uterus with 
a high risk of development and recurrence. LMS is 
responsible for 8% of uterine malignancies (1). About 
42%-60% of uterine sarcoma cases are related to various 
subtypes of LMS. Abnormal uterine bleeding (AUB) as 
well as pelvic pressure, pain and mass are considered as the 
first findings and symptoms of leiomyoma and sarcomas, 
which make it difficult to distinguish between them (2-4). 
LMS is usually diagnosed following a surgery, although in 
a rare condition, frozen section analysis is used during a 
surgery. Grade of the tumor and histopathological findings 
help physicians choose an appropriate clinical behavior 
and therapeutic approach. There is not a single reliable 
test to apply before the surgery to distinguish between a 
benign or malignant uterine disease. We used computed 
tomography (CT) scan results and histopathology report 
following an exploratory laparotomy to diagnose LMS 
in a 53-year-old G7 L7 woman who complained of AUB 
and rapidly growing abdominal mass. This study was 
a case report that discussed uterine LMS, the clinical 
characteristics, diagnosis, outcome, and recent advances.
Case Report
A 53-year-old G7 L7 woman, living in Zabol, Sistan and 
Baluchestan Province, Iran, suffering from AUB for 6 
months, was admitted to the emergency room of Zabol 
hospital, Zabol, Iran, with complaints of heavy vaginal 
bleeding and passing blood clots in January 2016. She 
had mild to moderate pain in the lower abdomen toward 
the epigastric area. The patient noticed a rapidly growing 
mass in the lower abdomen from 4 months ago. Patient 
also complained of abdominal bloating and loss of 
appetite. There was no symptom of painful bladder or 
bowl syndromes. Furthermore, there was no history of 
chronic or long-term diseases.
Physical Examination
On examination, patient looked pale and had stable vital 
signs with blood pressure (BP) of 120/79 mm Hg, pulse 
rate (PR) of 96 pulses/second, and respiratory rate (RR) 
of 18 breaths/minute. On the abdominal examination, 
a soft to firm, non-tender, mobile mass was palpated in 
the midline of abdominal area, spreading from lower 
abdomen to epigastric area.On vaginal examination, there 
was an enlarged anteverted uterus, like the size of 20 -week 
pregnancy. There was no cervical motion tenderness 
(CMT) and no bilateral tenderness on fornix palpation.
Investigation
The CT scan results showed a heterogeneous mass 
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Introduction 
Throughout the history of the world, the ones who had 
confronted the bitterest face of poverty and war had al-
ways been the women. As known poverty and war affects 
human health either directly or indirectly, the effects of 
this condition on health and status of women in the so-
ciety should not be ignored. This study intends to cast 
light on the effects of war and poverty on the reproductive 
health of women. For this purpose, the face of war affect-
ing the women, the problem of im igration, inequalities 
in distribution of i come based on gend r and the effects 
of all these on the reproductive health of women will be 
addressed.
War and Women’s Health
Famine, synonymous with war and poverty, is clearer for 
women; war means deep disadvantages such as full de-
struction, loss of future and uncertainty for women. Wars 
are conflicts that destroy families, societies and cultures 
that negatively affect the health of community and cause 
violation of human rights. According to the data of World 
Health Organization (WHO) and World Bank, in 2002 
wars had been amo g the first ten reasons which killed 
the most and caused disabilities. Civil losses are at the rate 
of 90% within all losses (1).
War has many negative effects on human health. One of 
these is its effect of shortening the average human life. 
According to the data of WHO, the average human life is 
68.1 years for males and 72.7 years for females. It is being 
thought that sever  military conflicts in Africa shorten 
the expected lifetime for more than 2 years. In general, 
WHO had calculated that 269 thousand people had died 
in 1999 due to the effect of wars and that loss of 8.44 mil-
lion healthy years of life had occurred (2,3).
Wars negatively affect the provision of health services. 
Health institutions such as hospitals, laboratories and 
health centers are direct targets of war. Moreover, the wars 
cause the migration of qualified health employees, and 
thus the health services hitches. Assessments made indi-
cate t at the effect of destruction in the infrastructure of 
health cont ues for 5-10 years even after the finalization 
of conflicts (3). Due to resource requirements in the re-
structuring investments after war, the share allocated to 
health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and 
children. While deaths depending on direct violence af-
fect the male population, the indirect deaths kill children, 
women and elders more. In Iraq between 1990-1994, in-
fant deaths had shown this reality in its mo  ba e form 
with an increase of 600% (4). The war taking five y ars 
increases the child deaths under age of 5 by 13%. Also 47% 
of all the refugees in the world and 50% of asylum seekers 
and displaced people are women and girls and 44% ref-
ugees and asylum seekers are children under the age of 
18 (5).
As the result of wars and armed conflicts, women are 
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with multilocular and multiseptated regions and  with 
approximate size of 93 × 121 cm, extending from pelvic 
area to epigastric area. The results also indicated that the 
mass possibly spread to the uterine body and anterior wall 
of myometrium while connecting to the uterus. 
Due to the pressure of the mass, the ovaries could not be 
checked. Free fluid was observed in the abdominal cavity. 
Muscle tissue and bone of hip region were normal and 
there was no sign of lymphadenopathy. Furthermore, the 
results of endometrial biopsy, performed on the patient 
in October 2015, indicated no presence of malignancy. At 
the same time, the report of Pap smear indicated chronic 
cervicitis, and in differential blood count, hemoglobin 
level was 11; therefore, based on these findings and vaginal 
bleeding from which the patient suffered, a surgery was 
performed on the patient in January 2016. During surgery, 
an enlarged uterus, like the size of 20-week pregnancy, was 
observed, while there was a connection of dense adhesions 
of the omentum to the mass and anterior abdominal wall. 
The mass was arisen from the uterine fundus originated 
from peritoneum and lobulated omentum (Figure 1). The 
samples from mass along with solid components, cystic 
and hemorrhage were then sent to the cytology laboratory 
of the hospital. Uterus, Fallopian tubes and ovaries were 
removed during the surgery, and the patient received 3 
units of packed red blood cells (RBC).
Macroscopic Features of Mass
The dissection of enlarged uterus revealed an oval-shaped 
mass with a size of 27 × 20 × 15 cm and diameter of 11 cm 
inside the uterus cavity that spread throughout the cervix. 
The cross-section of mass showed a gray-white, fleshy, and 
lobulated cut surface that contained foci of hemorrhage.
Microscopic Features of Mass
Evaluation of the tissue sections showed spindle cells 
containing hyperchromatic nuclei and eosinophilic 
cytoplasm. The taken images indicated mitotic (M) phase 
containing atypical mitosis (high-power fields [HPF] 
˃10/10) and foci of necrosis. The total findings suggested 
LMS with cervix involvement. Peritoneal washings (PW) 
cytologic analysis indicated no malignant cells. 
There was no post-operative complication. The patient 
was discharged 7 days after the operation in satisfactory 
condition. After pathology report, the patient was referred 
to a gynecologic oncologist for possible chemotherapy 
(Figures 2A-2E).
Discussion
LMS is considered and is known as an aggressive tumor 
with high mortality and morbidity (1,5). There is no 
reliable diagnostic method to distinguish between uterine 
LMS and benign uterine tumors before surgery. However, 
due to the increased levels of total lactate dehydrogenase 
(LDH) and LDH isoenzyme-3 in the patients with LMS, 
biochemical evaluations are also considered as a useful 
method. Among imaging studies, a high vascularity score 
in Doppler ultrasonography and high signal intensity in 
diffusion weighted imaging (DWI) also indicate malignant 
ovarian tumors (6). Diagnosis of LMS and determination 
of its stage are only based on the histopathology report 
after the surgery. Surgical staging of LMS includes 
hysterectomy and bilateral salpingo-oophorectomy 
(BSO). The tumor size larger than 5 cm and high mitotic 
Figure 1. Atypical Mitosis (H&E staining)
(×400). 
Figure 2. Uterine  Leiomyosarcoma. (A) Foci of coagulative tumor cell necrosis  (arrow) (×100). (B) Spindle cells arranged in interca-
lating bundle (arrow) (×100). (C) Uterine  Leiomyosarcoma (arrow) (×400). (D) Pronounced nuclear pleomorphism (arrow) (×400). (E) 
Nuclear pleomorphism and few mitotic figures (arrow) (H&E staining) (×400).
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index are considered as important prognostic factors (7). 
Hematogenous spread is the most common form, and 
lymphatic spread is the rare one. Sarcoma is known as an 
aggressive tumor, meaning that there is still a high risk 
of local and distant recurrence after the tumor removal 
(5). LMS in stages I and II, according to the International 
Federation of Gynecology and Obstetrics (FIGO) staging 
systems, has a very high risk of relapse, while its survival 
rate is also poor after relapse. A study has indicated that the 
survival rates of LMS I and II are 50% and 25%, respectively 
(8). Site of metastasis or recurrence is often around the 
liver and lungs, which is due to the hematogenous spread 
(9).The patients with early stage LMS do not really benefit 
from radiation therapy, while there is no overall survival 
benefit regarding the radiation therapy. Some prospective 
studies have also shown the effectiveness of chemotherapy 
in the treatment of uterine LMS (10). In our case, due 
to heavy bleeding, we had no time for doing further 
diagnostic evaluations; therefore, we decided for surgery 
.and considering the LMS-presented macroscopic and 
microscopic features. Then the patient was referred to a 
gynecologic oncologist.
Conclusion
Preoperative algorithm (low risk or high risk) should be 
attended in order to avoid the occurrence of unexpected 
LMS, diagnosed on the pathologic post-operative 
examination and after surgery selection; this should be 
done in the patients with the history of myoma or the 
patients highly suspicious to LMS. Clinical, biochemical, 
and ultrasonographic evaluations, suspicious of LMS, and 
a pelvic MRI only for highly suspected cases should be 
performed. We found that surgery is the only treatment 
for LMS. 
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